Forest Labs A: (NYSE: FRX)
$38.53
-0.17 (-0.44%)
Volume 990,205
May 17 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Full Company Report
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. Forest's most important United States products consist of branded ethical drug specialties marketed directly, or to physicians by the company's Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty Sales salesforces.
General Information
FOREST LABS A
909 THIRD AVENUE
NEW YORK, NY 10022
Phone: 2124217850
Fax: 2127509152
Web: http://www.frx.com
Email: Investor.Relations@frx.com
| Industry | MED-DRUGS |
| Sector | Medical |
| Fiscal Year End | March |
| Last Reported Quarter | 03/31/2013 |
| Next EPS Date | 07/16/2013 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 38.70 |
| 52 Week High | 39.09 |
| 52 Week Low | 31.28 |
| Beta | 0.75 |
| 20 Day Moving Average | 1,221,698.50 |
| Target Price Consensus | 38.23 |
% Price Change
| 4 Week | 8.72 |
| 12 Week | 5.97 |
| YTD | 9.57 |
Share Information
| Shares Outstanding (millions) | 266.28 |
| Market Capitalization (millions) | 10,259.92 |
| Short Ratio | 3.94 |
| Last Split Date | 01/09/03 |
% Price Change Relative to S&P 500
| 4 Week | 0.51 |
| 12 Week | -4.52 |
| YTD | -5.44 |
Dividend Information
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.09 |
| Current Year EPS Consensus Estimate | 0.90 |
| Estimated Long-Term EPS Growth Rate | 32.30 |
| Next EPS Report Date | 07/16/2013 |
Consensus Recommendations
| Current (1=Strong Buy, 5=Strong Sell) | 2.57 |
| 30 Days Ago | 2.27 |
| 60 Days Ago | 2.76 |
| 90 Days Ago | 2.78 |
Fundamental Ratios
P/E
| Current FY Estimate | 42.74 |
| Trailing 12 Months | 96.32 |
| PEG Ratio | 1.33 |
Price Ratios
| Price/Book | 1.81 |
| Price/Cash Flow | 8.63 |
| Price / Sales | 3.28 |
Current Ratio
| 03-31-13 | NA |
| 12-31-12 | 3.04 |
| 09-30-12 | 3.80 |
Net Margin
| 03-31-13 | -1.03 |
| 12-31-12 | 3.43 |
| 09-30-12 | 14.22 |
Inventory Turnover
| 03-31-13 | NA |
| 12-31-12 | 2.10 |
| 09-30-12 | 2.36 |
EPS Growth
| vs. Previous Year | -67.95% |
| vs. Previous Quarter | 219.05% |
ROE
| 03-31-13 | 1.85 |
| 12-31-12 | 4.33 |
| 09-30-12 | 10.26 |
Quick Ratio
| 03-31-13 | NA |
| 12-31-12 | 2.64 |
| 09-30-12 | 3.41 |
Pre-Tax Margin
| 03-31-13 | NA |
| 12-31-12 | 4.11 |
| 09-30-12 | 17.72 |
Debt-to-Equity
| 03-31-13 | NA |
| 12-31-12 | 0.00 |
| 09-30-12 | 0.00 |
Sales Growth
| vs. Previous Year | -22.17% |
| vs. Previous Quarter | 13.70% |
ROA
| 03-31-13 | 1.42 |
| 12-31-12 | 3.31 |
| 09-30-12 | 7.80 |
Operating Margin
| 03-31-13 | 3.40 |
| 12-31-12 | 7.38 |
| 09-30-12 | 15.11 |
Book Value
| 03-31-13 | NA |
| 12-31-12 | 21.31 |
| 09-30-12 | 21.78 |
Debt to Capital
| 03-31-13 | NA |
| 12-31-12 | 0.00 |
| 09-30-12 | 0.00 |
